Skip to main content
Oric Pharmaceuticals, Inc. logo

Oric Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ORIC ISIN · US68622P1093 LEI · 54930033FJRNEYBW0L25 US Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2026-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US ORIC

About Oric Pharmaceuticals, Inc.

https://oricpharma.com/

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. The company's platform addresses the primary mechanisms of therapeutic resistance—innate, acquired, and bypass—with the goal of making existing treatments more effective and durable. Its pipeline includes several targeted therapeutics in clinical development. Key programs include enozertinib (ORIC-114), an inhibitor being studied in non-small cell lung cancer (NSCLC) with specific EGFR/HER2 mutations, and ORIC-944, which is in trials for prostate cancer. Oric employs a precision oncology approach, using biomarkers to identify patient populations most likely to respond to its treatments.

Recent filings

Filing Released Lang Actions
DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
Proxy Solicitation & Information Statement
2026-04-28 English
4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer)
Director's Dealing
2026-02-26 English
8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 23, 2026. It discusses updates related to the company's at-the-market offering program and prospectus supplements for share sales. It includes legal opinions and consents as exhibits. The content is an update on financing activities and share sales, not a full financial report or earnings release. The document length is 4739 characters, which is relatively short and focused on a specific event rather than comprehensive financial data. Therefore, it fits best under Capital/Financing Update (CAP) as it provides information on fundraising and capital structure changes through share sales.
2026-02-23 English
10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer)
Annual Report FY 2025
2026-02-23 English
8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 23, 2026, reporting the issuance of a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain the financial results but only announces and furnishes the press release. The length is 3644 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces the release of a financial report or press release without containing substantive financial data should be classified as a Regulatory Filing (RNS), as it is a current report filing announcing results but not the earnings release itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-23 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.